Abstract
It has been demonstrated that bisphosphonate-based supportive therapy (pamidronate or zoledronate) reduces skeletal events (onset or progression of osteolytic lesions) both in patients with multiple myeloma (MM) and in cancer patients with bone metastasis. Bisphosphonates (eg, alendronate) are also indicated in the treatment of osteoporosis. Nevertheless, osteonecrosis of the jaw (ONJ) has been reported in some patients being treated with bisphosphonates. We present a series of 9 MM patients who developed ONJ after treatment with bisphosphonates and chemotherapy. All the patients in this case series had undergone tooth extraction for recurrent dental abscesses while taking bisphosphonates. We also review the diagnostic and therapeutic implications of this paradoxical complication associated with treatment of bone lesions in MM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191–1200.
Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphos-phonates in multiple myeloma. J Clin Oncol. 2002;20:3719–3736.
Miller RG. Osteoporosis in postmenopausal women: therapy options across a wide range of risk for fracture. Geriatrics. 2006;61:24–30.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117.
Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004;117:440–441.
Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphos-phonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83–93.
Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182:413–415.
Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417–418.
Schirmer I, Peters H, Reichart PA, Durkop H. Bisphosphonates and osteonecrosis of the jaw [in German]. Mund Kiefer Gesichtschir. 2005;9:239–245.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534.
Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw necrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120–123.
Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med. 2005;34:613–617.
Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854.
Lambertenghi-Deliliers G, Bruno E, Cortellezzi A, Fumagalli L, Morosini A. Incidence of jaw lesions in 193 patients with multiple myeloma. Oral Surg Oral Med Oral Pathol. 1988;65:533–537.
Witt C, Borges AC, Klein K, Neumann HJ. Radiographic manifestations of multiple myeloma in the mandible: a retrospective study of 77 patients. J Oral Maxillofac Surg. 1997;55:450–453.
Lae ME, Vencio EF, Inwards CY, Unni KK, Nascimento AG. Myeloma of the jaw bones: a clinicopathologic study of 33 cases. Head Neck. 2003;25:373–381.
Durie BGM, Katz M, McCoy J, Crowley J. Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia and Zometa use [abstract]. Blood. 2004;104:216a. Abstract 756.
Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682–689.
Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Med Oral Patol Oral Cir Bucal. 2005;(10 suppl 2):E88-E91.
Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005;128:738.
Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32:1123–1128.
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factor, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–1575.
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658–1668.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Capalbo, S., Delia, M., Diomede, D. et al. Jaw Osteonecrosis Associated with Use of Bisphosphonates and Chemotherapy: Paradoxical Complication of Treatment of Bone Lesions in Multiple Myeloma Patients. Int J Hematol 83, 439–442 (2006). https://doi.org/10.1532/IJH97.E0536
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.E0536